NAS:ALLK (USA) Also Trade In: Germany
Allakos Inc $ 132.33 3.7 (2.88%)
Warning! GuruFocus has detected 2 Severe warning signs with ALLK. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ALLK (Allakos Inc) from 2018 to Jan 23 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Allakos stock (ALLK) PE ratio as of Jan 23 2021 is 0. More Details
Allakos PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Allakos PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:AGIO NAS:CCXI NAS:BLUE NAS:BPMC NYSE:BHVN NAS:ARWR NAS:HALO NAS:PTCT NAS:DCPH NAS:VIR OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 975 Island Drive, Suite 201, Redwood City, CA, USA, 94065
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.